CLBT Stock Analysis: Cellebrite DI | NASDAQ
Software - Infrastructure | NASDAQ, USA | Market Cap: 3.074m USD | 12M Return: -29.2% | IL0011794802 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 17.4M
EPS Trend: 87.6%
Qual. Beats: -1
Rev. Trend: 99.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cellebrite DI Ltd. (NASDAQ: CLBT) is an Israel-based application software company that develops digital forensics and investigative analytics software for legally sanctioned investigations worldwide. The company operates across Europe, the Middle East, Africa, the Americas, and Asia-Pacific, serving law enforcement, government agencies, and private-sector clients with a platform that covers the full investigative lifecycle-from accessing and decrypting digital evidence to case management and AI-powered analytics.
Its product portfolio is anchored by the Guardian suite of evidence management and case management solutions, the Inseyets digital forensics software, and the Cellebrite Pathfinder analytics tool, which uses AI to accelerate review of large evidence datasets. Through its Corellium subsidiary, Cellebrite also offers mobile application security testing (Corellium Viper) and vulnerability research (Corellium Falcon), extending its business beyond traditional forensics into the broader mobile security testing market. Revenue is further supplemented by professional services, including training, certification, and advanced consulting.
Cellebrite serves a customer base that includes federal, state, and local law enforcement agencies, as well as corporations and service providers, addressing cases ranging from child exploitation and counter-terrorism to financial crimes and corporate IP theft. The company is classified within the Information Technology sector (GICS Sub-Industry: Application Software), is headquartered in Petah Tikva, Israel, and has been listed on the NASDAQ since its August 2021 IPO.
- US federal budget cuts threaten law enforcement software spending
- Subscription revenue mix shift pressures near-term growth but lifts margins
- AI-powered Pathfinder analytics adoption accelerates upsell
| Net Income: 58.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 27.36 > 1.0 |
| NWC/Revenue: 42.58% < 20% (prev 67.81%; Δ -25.22% < -1%) |
| CFO/TA 0.15 > 3% & CFO 153.0m > Net Income 58.8m |
| Net Debt (-419.3m) to EBITDA (113.6m): -3.69 < 3 |
| Current Ratio: 1.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (252.8m) vs 12m ago 1.53% < -2% |
| Gross Margin: 82.96% > 18% (prev 84.38%; Δ -1.42% > 0.5%) |
| Asset Turnover: 57.73% > 50% (prev 55.46%; Δ 2.27% > 0%) |
| Interest Coverage Ratio: 174.1 > 6 (EBIT TTM 91.1m / Interest Expense TTM 523k) |
| A: 0.22 (Total Current Assets 583.2m - Total Current Liabilities 364.2m) / Total Assets 994.3m |
| B: -0.07 (Retained Earnings -69.2m / Total Assets 994.3m) |
| C: 0.10 (EBIT TTM 91.1m / Avg Total Assets 890.9m) |
| D: 1.18 (Book Value of Equity 538.1m / Total Liabilities 456.2m) |
| Altman-Z'' = 3.14 = A |
| DSRI: 1.01 (Receivables 110.8m/93.1m, Revenue 514.3m/436.7m) |
| GMI: 1.02 (GM 84.38% / 82.96%) |
| AQI: 2.04 (AQ_t 0.37 / AQ_t-1 0.18) |
| SGI: 1.18 (Revenue 514.3m / 436.7m) |
| TATA: -0.09 (NI 58.8m - CFO 153.0m) / TA 994.3m) |
| Beneish M = -2.27 (Cap -4..+1) = BBB |
As of October 31, 2026, the stock is trading at USD 12.15 with a total of 1,741,417 shares traded. Over the past week, the price has changed by +0.41%, over one month by +11.16%, over three months by -16.61% and over the past year by -29.24%.
Current recommended Stop Loss: 11.20 (which is 7.8% or 2.2 ATR below the current price).
Cellebrite DI has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy CLBT.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15.4 | 26.4% |
P/E Trailing = 53.1739
P/E Forward = 35.7143
P/S = 5.977
P/B = 5.6518
Revenue TTM = 514.3m USD
EBIT TTM = 91.1m USD
EBITDA TTM = 113.6m USD
Long Term Debt = 17.5m USD (estimated: total debt 23.2m - short term 5.74m)
Short Term Debt = 5.74m USD (from shortTermDebt, last quarter)
Debt = 23.2m USD (from shortLongTermDebtTotal, last quarter) (leases 23.2m already included)
Net Debt = -419.3m USD (calculated: Debt 23.2m - CCE 442.5m)
Enterprise Value = 2.65b USD (3.07b + Debt 23.2m - CCE 442.5m)
Interest Coverage Ratio = 174.1 (Ebit TTM 91.1m / Interest Expense TTM 523k)
EV/FCF = 21.26x (Enterprise Value 2.65b / FCF TTM 124.9m)
FCF Yield = 4.70% (FCF TTM 124.9m / Enterprise Value 2.65b)
FCF Margin = 24.28% (FCF TTM 124.9m / Revenue TTM 514.3m)
Net Margin = 11.43% (Net Income TTM 58.8m / Revenue TTM 514.3m)
Gross Margin = 82.96% ((Revenue TTM 514.3m - Cost of Revenue TTM 87.6m) / Revenue TTM)
Gross Margin QoQ = 80.78% (prev 82.53%)
Tobins Q-Ratio = 2.67 (Enterprise Value 2.65b / Total Assets 994.3m)
Interest Expense / Debt = 2.25% (Interest Expense 523k / Debt 23.2m)
Taxrate = 22.05% (16.6m / 75.4m)
NOPAT = 71.0m (EBIT 91.1m * (1 - 22.05%))
Current Ratio = 1.53 (Total Current Assets 583.2m / Total Current Liabilities 382.3m)
Debt / Equity = 0.04 (Debt 23.2m / totalStockholderEquity, last quarter 538.1m)
Debt / EBITDA = -3.69 (Net Debt -419.3m / EBITDA 113.6m)
Debt / FCF = -3.36 (Net Debt -419.3m / FCF TTM 124.9m)
Total Stockholder Equity = 495.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.60% (Net Income 58.8m / Total Assets 994.3m)
RoE = 11.87% (Net Income TTM 58.8m / Total Stockholder Equity 495.2m)
RoCE = 17.77% (EBIT 91.1m / Capital Employed (Equity 495.2m + L.T.Debt 17.5m))
RoIC = 11.64% (NOPAT 71.0m / Invested Capital 610.1m)
WACC = 6.89% (E(3.07b)/V(3.10b) * Re(6.93%) + D(23.2m)/V(3.10b) * Rd(2.25%) * (1-Tc(0.22)))
Discount Rate = 6.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 84.56 | Cagr: 11.76%
[DCF] Terminal Value 75.44% ; FCFF base≈124.9m ; Y1≈125.4m ; Y5≈132.8m
[DCF] Fair Price = 9.89 (EV 2.07b - Net Debt -419.3m = Equity 2.49b / Shares 251.3m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 87.63 | EPS CAGR: 24.08% | SUE: -1.97 | # QB: -1
Revenue Correlation: 99.72 | Revenue CAGR: 20.55% | SUE: -0.35 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.16 | Chg30d=+0.00% | Revisions=+18% | Analysts=8
EPS current Year (2026-12-31): EPS=0.55 | Chg30d=+0.00% | Revisions=-10% | GrowthEPS=+7.6% | GrowthRev=+17.0%
EPS next Year (2027-12-31): EPS=0.65 | Chg30d=+0.00% | Revisions=-10% | GrowthEPS=+19.1% | GrowthRev=+15.1%
[Analyst] Revisions Ratio: +0% (up=11, down=11)